RetiPharma IVS: Financial statements 2017
CVR: 37134120
Source: annual report 2017, Danish Business Authority
01/01/2017 – 31/12/2017
RetiPharma IVS (CVR 37134120) has filed annual accounts for 2017. In 2017, the company reported a gross profit of DKK 0 and a net result of DKK 0. Equity in the 2017 report amounted to DKK 1. The solvency ratio was 100%.
- Revenue
- DKK 0
- Gross Profit
- DKK 0
- Profit/Loss
- DKK 0
- Equity
- DKK 1
- Total Assets
- DKK 1
Official annual report
Keep an eye on RetiPharma IVS
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2017
RetiPharma IVS has published its interim report for the period September 10, 2015 – December 31, 2016.
As of October 4, 2017, Kristian Klemp is registered as director of RetiPharma IVS.
As of October 4, 2017, David Paul Drucker Woldbye is registered as adm. dir. of RetiPharma IVS.
As of August 31, 2017, Kristian Klemp has stepped down as director of RetiPharma IVS.
As of August 31, 2017, David Paul Drucker Woldbye has stepped down as adm. dir. of RetiPharma IVS.
About RetiPharma IVS
RetiPharma IVS was a Danish company of the type Iværksætterselskab based in København N, founded in 2015. The company has been dissolved on 25 September 2020. The company was registered under the industry Anden teknisk rådgivning. The company has 4 employees (2018). In 2018, the company reported a gross profit of DKK -147,051 and a net result of DKK -203,870 compared with DKK 0 the year before. Equity in the 2018 report amounted to DKK -190,437.